SAN DIEGO, June 9, 2021 /PRNewswire/ -- BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving [...]
SAN DIEGO, May 25, 2021 /PRNewswire/ -- BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving [...]
First molecular glue program, BTX-1188, expected to enter the clinic by the end of 2021 Additional protein degradation programs [...]
SAN DIEGO, May 18, 2021 /PRNewswire/ -- BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving [...]
SAN DIEGO, May 4, 2021 /PRNewswire/ -- BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving [...]
SAN DIEGO, April 7, 2021 /PRNewswire/ -- BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving [...]
SAN DIEGO, March 3, 2021 /PRNewswire/ -- BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving [...]
SAN DIEGO, Feb. 15, 2021 /PRNewswire/ -- BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines, [...]
SAN DIEGO, Jan. 7, 2021 /PRNewswire/ -- BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving [...]
SAN DIEGO, Jan. 7, 2021 /PRNewswire/ -- BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving [...]